Abstract:Hematopoietic stem cell transplantation (HSCT) is the only curative option available for patients with thalassemia major in India with increasing access to alternate donor transplantation for patients with no matched family donor. We aimed to analyze the impact of family and alternate donor HSCT on morbidity and mortality post-HSCT. We conducted a retrospective study in the department between July 2007 and December 2018 where all children who underwent HSCT for thalassemia major were included. A total of 264 children were included with a median age of 6 years (male/female, 1.4:1). The graft source was matched related donor (MRD) (76%; parent 15%, sibling 85%) and matched unrelated donor (MUD) (22%). All children received a myeloablative conditioning regimen with treosulfan/thiotepa/fludarabine in 93% and busulfan/cyclophosphamide in 7%. The source of stem cells was peripheral blood in 61%, bone marrow in 38%, and umbilical cord blood in 3%. The incidence of bacteremia was 14% versus 25% in MRD versus MUD groups. There was a higher incidence of posterior reversible encephalopathy syndrome (PRES) in the MUD group (10% versus 3%). Engraftment occurred in 97% with a higher trend toward mixed chimerism in the MRD group (12% versus 2%). When indicated, whole-blood donor lymphocyte infusion was used to ensure complete chimerism in children in the MRD group. A statistically significant difference was found in the incidence of graft versus host disease (GVHD), both acute and chronic between the MUD versus MRD groups, 60% versus 20% and 41% versus 17%, respectively (P = .001). Similarly, immune cytopenia and cytomegalovirus reactivation were also significantly higher in the MUD group, 27% versus 1.4% and 25% versus 2%, respectively (P = .001). Thalassemia-free survival in our cohort was 96%, 94%, and 84% with a median follow-up of 65 months in the matched sibling donor, matched family donor, and MUD groups, respectively. Overall survival of 95% and 90% with a median follow-up of 65 months was noted in those who underwent transplantation less than and greater than 7 years of age, respectively. MUD transplantation for patients with thalassemia major involves specific challenges such as PRES and unusual manifestations of GVHD such as immune cytopenia. Early interventions to optimize supportive care and measures to reduce GVHD are required to ensure survival rates of over 90%.

[Comparision of Allogeneic Hematopoietic Stem Cell Transplantation Between Children with Thalassemia of Different Ages].

Comparison of Hematopoietic Stem Cell Transplantation Results in Patients with β-Thalassemia Major from Three Different Graft Types

Outcome of 64 Aplastic Anemia Children with Allogenic Hematopoietic Stem Cell Transplant in China: A Report from Chinese Pediatric Group of HSCT

[Therapeutic Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Children with Chronic Myelogenous Leukemia].

Pediatric hematopoietic stem cell transplantation in China: Data and trends during 1998–2012

Outcomes of blood and marrow transplantation in children less than 2-years of age: 23 years of experience at a single center

Hematopoietic Stem Cell Transplantation in Children with Sickle Cell Disease and Thalassemia Major: A National Database Study

Busulfan-Based and Treosulfan-Based Myeloablative Conditioning for Allogeneic Transplantation in Children with Thalassemia Major: a Single-Center Experience From Southern Turkey

Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South India

Clinical Analysis of 10 with Aplastic Anemia Children after Allogeneic Hematopoietic Stem Cell Transplantation

Health-Related Quality-of-Life Profile of Pediatric Patients with β Thalassemia after Hematopoietic Stem Cell Transplantation

Comparison of Efficacy Between HLA6/6- and HLA3/6-matched Haploidentical Hematopoietic Stem Cell Transplant in T-cell-replete Transplants Between Parents and Children

Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience

Hematopoietic Stem Cell Transplantation for Children with Β-Thalassemia Major: Multicenter Experience in China.

Transplantation of Haploidentical Hematopoietic Stem Cells from Family Members Without in Vitro T-cell Depletion for Treatment of Hematologic Malignancies in Pediatric Patients

Safety and efficacy of peripheral blood stem cells collection in healthy children and pediatric patients with thalassemia major weighing 20 kg or less

Outcome of allogeneic hematopoietic stem cell transplantation for children with high-risk acute myeloid leukemia

The growth and development of children with β-thalassemia major one year after allogeneic hematopoietic stem cell transplantation

First‐line Choice for Severe Aplastic Anemia in Children: Transplantation from a Haploidentical Donor Vs Immunosuppressive Therapy

Survival and late effects of hematopoietic cell transplantation in patients with thalassemia major

Haploidentical Stem Cell Transplantation in Patients Aged 50yr and Older with Leukemia: Similar Outcomes Compared to Younger Adults